Societal CDMO, Inc. (NasdaqCM: SCTL)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Societal CDMO, Inc. (NasdaqCM: SCTL) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Societal CDMO, Inc. across four factors: quality 43/100. Its strongest factor is quality.
SCTL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $94.64M
- P/E
- —
- EPS
- -0.14
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 258
- Next earnings
- —
About Societal CDMO, Inc.
Societal CDMO, Inc., an organization founded in Exton, Pennsylvania, in 2007, functions as a contract development and manufacturing partner for the global pharmaceutical industry. Formerly known as Recro Pharma, Inc. until its name change in March 2022, the company specializes in supporting small molecule therapeutic advancements. Its comprehensive services span the entire drug development lifecycle, from initial research and development to manufacturing and packaging various therapeutic dosage forms for both domestic and international markets. Key offerings include drug development expertise, end-to-end regulatory guidance, clinical and commercial scale production, sterile fill/finish operations, freeze-drying (lyophilization), and integrated packaging and logistics solutions.
- ISIN
- US75629F1093
- Founded
- 2007
- Listed since
- Mar 7, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.